Boehringer Ingelheim builds on its biologics lead

被引：0
|
作者：
Hunter, D
机构：
来源：
CHEMICAL WEEK | 2002年 / 164卷 / 24期
关键词：
Antibodies - Bioreactors - Biotechnology - Catalysis - Cells - Customer satisfaction - Diseases - DNA - Drug products - Fermentation - Forecasting - Hydrogenation;
D O I：
暂无
中图分类号：
TQ [化学工业];
学科分类号：
0817 ;
摘要：
Boehringer Ingelheim, a top 20 pharmaceutical producer contract manufacturing company, is riding high on the booming demand for contract biologicals manufacturing capacity. The company has 30% worldwide market share for mammalian cell-based production. The company also operates microbial fermentation-based biologicals manufacturing capacity. It is developing an exclusive synthesis business to provide third party contract manufacturing of intermediates for new pharmaceutical entities, using the company's plants.
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
12345